Horizon Pharma's phase 3 study of Lodotra demonstrates 12 month sustained efficacy & safety in RA
Tuesday, July 27, 2010 13:00 IST Northbrook, Illinois
Horizon Pharma, Inc announced results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) phase-3 European registration study of Lodotra